Zambia’s Use of PEPFAR HIV Treatment as Mineral Leverage Risks Public Health and US Leadership

It might seem like a world away from the bustling streets of Washington, D.C., but the geopolitical maneuvering currently unfolding in Southern Africa is hitting home for those of us in the nation’s capital. When the U.S. Government considers leveraging life-saving medication as a bargaining chip for mineral rights, it isn’t just a diplomatic strategy—it’s a decision that echoes through the halls of the State Department and the corridors of the CDC’s headquarters right here in our backyard. For the policy analysts and global health experts who call the District home, the threat to cut HIV relief to Zambia is more than a headline; This proves a fundamental shift in how the United States projects its leadership on the global stage.

The High Stakes of the PEPFAR Pivot

To understand the gravity of the current situation, we have to look at the scale of the President’s Emergency Plan for AIDS Relief (PEPFAR). Since its inception in 2003, PEPFAR has been the largest commitment by any single nation to address a single disease in history, investing nearly $100 billion to combat the HIV pandemic. In Zambia, this partnership has been transformative. The U.S. Embassy in Zambia reports that the country has exceeded UNAIDS HIV targets in treatment and viral suppression, a feat achieved through close collaboration between the Zambian government, faith-based organizations, and civil society.

However, recent reports indicate a volatile shift in strategy. A draft memo prepared for Secretary of State Marco Rubio suggests that the Trump administration may “significantly cut” HIV relief as early as May if Zambia does not grant the U.S. Increased access to its natural minerals. The memo explicitly states a willingness to “publicly take support away from Zambia on a massive scale” to secure U.S. Priorities. This approach treats humanitarian aid not as a public health imperative, but as a negotiating tool for resource extraction.

The Human Cost of Diplomatic Leverage

The numbers associated with this potential cut are staggering. An estimated 1.3 million people in Zambia rely on antiretroviral medications, with 42 percent of those drugs provided through PEPFAR. Over the last two decades, Zambia has received more than $6 billion in support, which includes critical medications to prevent babies from being infected with HIV at birth. The proposed latest deal would provide Zambia with $1 billion in health funding over five years—less than half of what the country received before the current administration’s second term began.

From a public health perspective, Here’s a dangerous gamble. The CDC has spent 25 years working with the Zambian Ministry of Health (MOH) to build sustainable capacity. Their efforts include the implementation of the SmartCare National Electronic Health Record system, which is used in over 1,600 high-volume facilities and supports over 2 million people. By disrupting the flow of medication and funding, the U.S. Risks undoing decades of progress in case identification and linkage for pediatrics and young people. When treatment is interrupted, the risk of drug resistance increases, which could potentially lead to a resurgence of the epidemic and a loss of trust in U.S. Global health initiatives.

Navigating the Fallout in Washington, D.C.

For those of us living and working in the District, these global shifts often translate into local professional volatility. Whether you are a consultant for a multilateral partner or a researcher at a major university, the pivot toward “transactional diplomacy” creates a ripple effect. We are seeing a shift where the global health landscape is being redrawn, and the professionals managing these portfolios must now navigate a landscape where health outcomes are tied to mining concessions.

This isn’t just about Zambia; it’s about the precedent being set. PEPFAR currently supports nearly 20 million people worldwide with antiretroviral therapy and has helped 1.95 million people enroll in pre-exposure prophylaxis (PrEP) in the last year alone. If aid becomes a tool for mineral leverage, the stability of health systems in over 50 countries could be called into question, impacting the very surveillance networks the CDC uses to prevent health threats from reaching the U.S.

Local Resource Guide for D.C. Professionals

Given my background in analyzing the intersection of policy and public health, I realize that when global strategies shift this abruptly, the local professionals tasked with implementing these changes face immense pressure. If you are working within the D.C. Ecosystem and uncover your project or organization impacted by these shifts in foreign assistance, you require a specific set of experts to help you pivot.

International Regulatory Compliance Consultants

Look for specialists who specifically handle USAID and State Department funding regulations. You need professionals who can audit current grants and identify “bridge funding” opportunities or private-sector alternatives when government funding is suddenly withdrawn or conditioned upon non-health mandates.

Geopolitical Risk Analysts

Seek out analysts who specialize in Sub-Saharan African markets and resource diplomacy. The ideal professional should be able to provide “second-order” impact reports—explaining not just the loss of funding, but how the shift toward mineral-based negotiations affects the stability of local health infrastructure and U.S. Diplomatic standing.

Global Health Policy Strategists

You need experts who have a proven track record of transitioning government-led programs (like the Government-to-Government model used by the CDC) into sustainable, locally-led initiatives. Look for those with experience in “localization” strategies that can protect patient care even when bilateral relations sour.

Ready to find trusted professionals? Browse our complete directory of top-rated us experts in the washington dc area today.